

01st February, 2023

BSE Limited

P.J. Towers, Dalal Street, Fort,
Mumbai- 400 001
BSE scrip code: 543635

National Stock Exchange of India Limited

Exchange Plaza, Bandra-Kurla Complex,
Bandra (East), Mumbai – 400 051
NSE symbol: PPLPHARMA

Sub: Regulation 29 and Regulation 50 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations')

**Unaudited Financial Results (Standalone and Consolidated) for the quarter and Nine months ended 31st December, 2022
Board Meeting on 08th February, 2023**

Dear Sir / Madam,

Pursuant to Regulations 29 and 50 of the Listing Regulations, we write to inform you that a meeting of the Board of Directors of the Company will be held on Wednesday, 08th February, 2023, *inter alia* to consider and approve the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter and nine months ended 31st December, 2022.

In this regard, we write to inform you that the 'Trading Window' for dealing in the securities of the Company, which has been closed from Sunday 01st January, 2023 will remain closed till Friday, 10th February, 2023 (both days inclusive).

Thanking you,

Yours truly,

For **Piramal Pharma Limited**

Tanya Sanish
Company Secretary

Piramal Pharma Limited

CIN: U24297MH2020PLC338592

Registered Office: Gr. Flr. Piramal Ananta, Agastya Corporate Park, Opp Fire Brigade, Kamani Junction, LBS Marg, Kurla (West), Mumbai – 400070 India

T +91 22 3802 3000 / 4000

piramal.com